Wyeth Investors Likely To Win Class Cert. In Pristiq Case
Investors led by a pipe fitters union have asked to go forward as a class in a suit claiming Wyeth, then an independent company, committed securities fraud by failing to disclose heart- and liver-related side effects that appeared during Pristiq's clinical trials.
“I'm going to reserve [judgment] but...
To view the full article, register now.